In-house programs are focussed on auto-immune, anti-inflammatory and anti-angiogenesis conditions where current first-line small molecule and biologic therapies are failing to deliver the required disease outcomes for many patients.

Using the inherent qualities of their small size, stable nature and unique neutralisation potencies, Elasmogen is developing site-specific soloMERs that can deliver rapid alleviation of disease, minimise systemic exposure and side-effects and offer the promise of self-administered, longer-term treatments.

Elasmogen is also exploiting the flexible formatting options of our soloMERs (bi-specific, bi-paratopic, quadravalent) to deliver systemic “super-neutralisers“ that are approaching one order of magnitude more potent than equivalent clinical antibodies, but are almost half their size.

See publications section of our website for the data that supports these programs